Articles from March 2013

Amorfix Announces Progress on ALS Program

TORONTO, Canada, March 20, 2013 /CNW/ — Amorfix Life Sciences announced today that it has furthered the development of the first effective blood test to diagnose amyotrophic lateral sclerosis (ALS) by cloning ultra-high affinity antibodies that detect a misfolded version of the enzyme superoxide dismutase 1 (SOD1), which has been implicated  in the development of [...]

Results of NurOwn™ Clinical Trial Suggest Efficacy in ALS Patients

Data Indicate Initial Clinical Benefit in Overall Clinical and Respiratory Function
NEW YORK, NY and PETACH TIKVAH, ISRAEL, March 21, 2013 — BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, today reported some of the final results from a clinical study evaluating the company’s NurOwn™ technology in 12 ALS patients. NurOwn [...]

New Breathing Device Helps Patients Battle Lou Gehrig’s Disease

“This innovative diaphragm pacing system is an exciting development in the treatment of ALS. It has the potential to improve and extend the lives of hundreds of ALS patients. It is thrilling that our BWH team is able to bring this new treatment to ALS patients in New England,” said Dr. Ducko.

With A.L.S. in Family, Chief at Bloomberg Joins Fight

At a time when scientists are making rapid gains in the genetic roots of many diseases, Mr. Doctoroff, a former deputy mayor and private equity investor, is working with Mayor Michael R. Bloomberg and a private equity director, David M. Rubenstein, to put together a $25 million package of donations to support research to try to cure this rare and usually fatal degenerative neurological illness.

Up-and-Coming ALS Mice Leave Scientists ConFUSed

Mouse engineers presented the latest models overexpressing the amyotrophic lateral sclerosis gene fused in sarcoma (FUS) at “New Frontiers in Neurodegenerative Disease Research,” a Keystone Symposium held 4-7 February 2013 in Santa Fe, New Mexico. These animals have been four years in the making. This is a long time even for mice (see ARF related [...]

Spastic Paraplegia Foundation and Northeast ALS Consortium Announce Two Year, $200,000 Research Grant

SPF/NEALS Fellowship Grant intended to further cutting-edge research into ALS’s little-known cousin, Primary Lateral Sclerosis (PLS).
COLUMBUS, Ohio, February 21, 2013  — (24-7PressRelease) The Spastic Paraplegia Foundation (SPF) and the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) have announced the first Virginia Freer-Sweeney Clinical Research Training Fellowship in primary lateral sclerosis (PLS). The fellowship highlights another successful [...]

Unique ALS ‘Exome-Sequencing’ Project Is Focus of New Grant

MDA has awarded a $400,000 grant to National Institutes of Health (NIH) Laboratory of Neurogenetics researchers to perform exome sequencing on samples taken from 1,000 people with sporadic amyotrophic lateral sclerosis (ALS). The project will be led by neurologist Bryan Traynor, head of the Neuromuscular Diseases Research Group at the NIH in Bethesda, Md.

Bloomberg Targets Lou Gehrig’s Disease

Daniel L. Doctoroff, chief executive officer and president of Bloomberg LP; David M. Rubenstein, co-CEO of The Carlyle Group; and Bloomberg Philanthropies said Target ALS is a $25 million three-year initiative to tackle ALS in a different way.

New Study Shows Stem Cells’ Promise as Future ALS Treatment

A new study in the current issue of STEM CELLS Translational Medicine demonstrates how human stem cells can successfully engraft, survive and differentiate into mature neurons in the spinal cord of a rat with amyotrophic lateral sclerosis (ALS). The results offer new hope for those suffering from this disease, which generally ends in death within three to five years after diagnoses.

Identification of Abnormal Protein May Help Diagnose, Treat ALS and Frontotemporal Dementia

“In identifying the novel protein that abnormally accumulates in the brains of affected patients, we have uncovered a potentially new therapeutic target and biomarker that would allow clinicians to confirm diagnosis of the diseases,” says senior author Dr. Leonard Petrucelli, Chair of Neuroscience at Mayo Clinic in Florida.